Year: 2019

Gilat Achieves Fastest Ever Modem Speeds of 1.2 Gbps Total Throughput over Telesat’s Phase 1 LEO Satellite

Written by Customer Service on November 21, 2019. Posted in Public Companies.

PETAH TIKVA, Israel, Nov. 21, 2019 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (NASDAQ, TASE: GILT), a worldwide leader in satellite networking technology, solutions and services, announced today that Gilat achieved the fastest ever modem speeds of 1.2 Gbps total throughput over Telesat’s Phase 1 LEO satellite. This industry milestone demonstrates the potential of high throughput Non-Geostationary Orbit (NGSO) satellite constellations. Gilat’s technology opens opportunities for new telecommunications products and a wider range of customer experiences to markets demanding very high throughputs such as cruise ships, large airplanes, trunking and high-capacity government applications. Additionally, the combination of high throughput provided by Gilat’s innovative technology and the low latency from NGSO creates opportunity...

Myriad Genetics Announces Regulatory Approval of the BRACAnalysis® Diagnostic System in Japan for Breast Cancer Patients

Written by Customer Service on November 21, 2019. Posted in Public Companies.

SALT LAKE CITY, Nov. 21, 2019 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the BRACAnalysis® Diagnostic System (i.e., “BRACAnalysis”) to help physicians determine which women with breast cancer have Hereditary Breast and Ovarian Cancer (HBOC) syndrome and qualify for additional medical management. BRACAnalysis is a genetic test that identifies germline mutations in the BRCA1/2 genes. “We are excited that the MHLW has approved the BRACAnalysis Diagnostic System for HBOC risk assessment in patients with breast cancer,” said Seigo Nakamura, M.D., Ph.D., Professor and Chairman, Department of Surgery, Division of Breast Surgical Oncology and Director, Breast Center of Showa University...

Form 8.3 – Wincanton plc

Written by Customer Service on November 21, 2019. Posted in Mergers And Acquisitions.

FORM 8.3PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)1. KEY INFORMATION2. POSITIONS OF THE PERSON MAKING THE DISCLOSUREIf there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)All interests and all short positions should be disclosed.Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should...

Ooredoo Kuwait Chooses Fortinet to Deliver the Region’s First Secure SD-WAN Managed Service to Enterprise Customers

Written by Customer Service on November 21, 2019. Posted in Public Companies.

SUNNYVALE, Calif., Nov. 21, 2019 (GLOBE NEWSWIRE) — Fortinet® (NASDAQ: FTNT), a global leader in broad, integrated and automated cybersecurity solutions, today announced that it has been chosen by Ooredoo Kuwait, a part of Ooredoo Group – a leading international communications company operating across the Middle East, North Africa and Southeast Asia – to deliver the region’s first secure SD-WAN managed service. Fortinet Secure SD-WAN will allow Ooredoo’s existing and new enterprise customers to achieve accelerated connectivity, transport mode independence, and increased application performance while benefiting from tightly knit SD-WAN and advanced security features. Ooredoo Kuwait itself is deploying Fortinet’s Secure SD-WAN across its retail branches and will serve as a reference for customers wishing to follow suit.“Ooredoo Kuwait’s...

Entera Bio Establishes U.S. Headquarters and Announces Jonathan Lieber as Chief Financial Officer

Written by Customer Service on November 21, 2019. Posted in Public Companies.

BOSTON and JERUSALEM, Nov. 21, 2019 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX) today announced that it has established a U.S. Headquarters in the Boston area and has hired Jonathan Lieber as its U.S.-based CFO. Mr. Lieber will be responsible for all investor relations, finance and administrative functions, and will lead the Company’s future financing efforts to support the company’s growth initiatives.“We are pleased to have an accomplished executive of Jon’s caliber join Entera Bio. We welcome his long experience at emerging life science companies and his strong investor and banking relationships,” stated Adam Gridley, CEO of Entera. “As the company builds its presence with its stakeholders, the addition of Jon as our U.S.-based CFO will be critical to support our future growth, and our lead clinical programs and in our...

Iovance Biotherapeutics Announces Results of a Subgroup Analysis of Patients in the Lifileucel Metastatic Melanoma Study who are Primary Refractory to Anti-PD-1/L1 Therapy

Written by Customer Service on November 21, 2019. Posted in Public Companies.

– 41 percent objective response rate (ORR) as assessed by the investigator in 42 patients who were primary refractory to anti-PD-1/L1 therapy – – Median duration of response (DOR) was not reached as assessed by investigator at 12 months of study follow-up for the primary refractory subgroup –SAN CARLOS, Calif., Nov. 21, 2019 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced results of a subgroup analysis of Cohort 2 of the Phase 2 lifileucel metastatic melanoma study C-144-01 in patients who were primary refractory to prior anti-PD-1/L1 therapy. An abstract with details of the analysis was accepted as a late-breaking poster at the 16th International Congress of the Society for...

Axogen, Inc. to Participate at Piper Jaffray 31st Annual Healthcare Conference

Written by Customer Service on November 21, 2019. Posted in Public Companies.

ALACHUA, Fla., Nov. 21, 2019 (GLOBE NEWSWIRE) — Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president, will present at the Piper Jaffray 31st Annual Healthcare Conference in New York City. The presentation is scheduled for Thursday, December 5, 2019 at 8:10 a.m. ET.The presentation will be webcast live and accessible through the Investors page at www.axogeninc.com. For those not available to listen to the live broadcast, a replay will be archived for 90 days and available through the Investors page on www.axogeninc.com.About AxogenAxogen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve...

Calibre Mining Reports Temporary Suspension of Blasting Activities at its Jabali Underground Mine at La Libertad; Reaffirms 2019 Consolidated Guidance

Written by Customer Service on November 21, 2019. Posted in Public Companies.

VANCOUVER, British Columbia, Nov. 21, 2019 (GLOBE NEWSWIRE) — Calibre Mining Corp. (TSX: CXB) (the “Company” or “Calibre”) announces the temporary suspension of blasting activities at its Jabali underground mine at La Libertad. The suspension is related to surface instability issues caused by localised artisanal mining. The Company is supporting the government and community to mitigate the risks facing approximately 25 households in the community of Santo Domingo, proximal to the Jabali underground mine. The Company expects to resume blasting and full mining activities at Jabali underground prior to year-end. Mining at the Jabali open-pit remains unaffected and the Company continues to process ore at its La Libertad mill. Despite the temporary suspension of blasting at Jabali underground, the Company has reaffirmed its fourth quarter...

Baudax Bio™ Launches as a New Pharmaceutical Company Aimed at Advancing Promising, Non-Opioid Analgesic Therapies

Written by Customer Service on November 21, 2019. Posted in Public Companies.

Company Launches with $19 Million in Funding and Rights to IV Meloxicam, Along with Other Clinical-Stage Pipeline AssetsTrading of “BXRX” Begins Tomorrow on NASDAQMALVERN, Pa., Nov. 21, 2019 (GLOBE NEWSWIRE) — Baudax Bio, Inc. (NASDAQ:BXRX) today announced its launch as an independent, publicly traded pharmaceutical company focused on advancing non-opioid analgesics and other products for the hospital and other acute care settings. Beginning tomorrow, November 22, 2019, Baudax will trade on the NASDAQ Capital Market under the ticker symbol “BXRX.” When-issued trading under the symbol “BXRXV” continues until market close today.“Baudax Bio will pursue the development of therapeutics, specifically focusing on innovative products for acute care settings where there is an urgent need and the potential for the greatest impact for patients,”...

Molecular Templates, Inc. Announces Pricing of $50.0 Million Public Equity Offering

Written by Customer Service on November 21, 2019. Posted in Public Companies.

AUSTIN, Texas, Nov. 21, 2019 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer, today announced the pricing of its underwritten public offering of 6,000,000 shares of its common stock at a public offering price of $8.00 per share and 250 shares of its newly designated Series A convertible preferred stock at a public offering price of $8,000 per share. Each share of Series A convertible preferred stock will be convertible into 1,000 shares of common stock at the holder’s option, subject to beneficial ownership limitations. All of the shares of common stock and Series A convertible...

Year: 2019

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals